Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

Pain therapeutics from cone snail venoms : From Ziconotide to novel non-opioid pathways. / Safavi-Hemami, Helena; Brogan, Shane E; Olivera, Baldomero M.

I: Journal of Proteomics, Bind 190, 2019, s. 12-20.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Safavi-Hemami, H, Brogan, SE & Olivera, BM 2019, 'Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways', Journal of Proteomics, bind 190, s. 12-20. https://doi.org/10.1016/j.jprot.2018.05.009

APA

Safavi-Hemami, H., Brogan, S. E., & Olivera, B. M. (2019). Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. Journal of Proteomics, 190, 12-20. https://doi.org/10.1016/j.jprot.2018.05.009

Vancouver

Safavi-Hemami H, Brogan SE, Olivera BM. Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways. Journal of Proteomics. 2019;190:12-20. https://doi.org/10.1016/j.jprot.2018.05.009

Author

Safavi-Hemami, Helena ; Brogan, Shane E ; Olivera, Baldomero M. / Pain therapeutics from cone snail venoms : From Ziconotide to novel non-opioid pathways. I: Journal of Proteomics. 2019 ; Bind 190. s. 12-20.

Bibtex

@article{baa104a77e3a405da19e47756f62e5ee,
title = "Pain therapeutics from cone snail venoms: From Ziconotide to novel non-opioid pathways",
abstract = "There have been numerous attempts to develop non-opioid drugs for severe pain, but the vast majority of these efforts have failed. A notable exception is Ziconotide (Prialt{\textregistered}), approved by the FDA in 2004. In this review, we summarize the present status of Ziconotide as a therapeutic drug and introduce a wider framework: the potential of venom peptides from cone snails as a resource providing a continuous pipeline for the discovery of non-opioid pain therapeutics. An auxiliary theme that we hope to develop is that these venoms, already a validated starting point for non-opioid drug leads, should also provide an opportunity for identifying novel molecular targets for future pain drugs. This review comprises several sections: the first focuses on Ziconotide as a therapeutic (including a historical retrospective and a clinical perspective); followed by sections on other promising Conus venom peptides that are either in clinical or pre-clinical development. We conclude with a discussion on why the outlook for discovery appears exceptionally promising. The combination of new technologies in diverse fields, including the development of novel high-content assays and revolutionary advancements in transcriptomics and proteomics, puts us at the cusp of providing a continuous pipeline of non-opioid drug innovations for pain. SIGNIFICANCE: The current opioid epidemic is the deadliest drug crisis in American history. Thus, this review on the discovery of non-opioid pain therapeutics and pathways from cone snail venoms is significant and timely.",
author = "Helena Safavi-Hemami and Brogan, {Shane E} and Olivera, {Baldomero M}",
year = "2019",
doi = "10.1016/j.jprot.2018.05.009",
language = "English",
volume = "190",
pages = "12--20",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Pain therapeutics from cone snail venoms

T2 - From Ziconotide to novel non-opioid pathways

AU - Safavi-Hemami, Helena

AU - Brogan, Shane E

AU - Olivera, Baldomero M

PY - 2019

Y1 - 2019

N2 - There have been numerous attempts to develop non-opioid drugs for severe pain, but the vast majority of these efforts have failed. A notable exception is Ziconotide (Prialt®), approved by the FDA in 2004. In this review, we summarize the present status of Ziconotide as a therapeutic drug and introduce a wider framework: the potential of venom peptides from cone snails as a resource providing a continuous pipeline for the discovery of non-opioid pain therapeutics. An auxiliary theme that we hope to develop is that these venoms, already a validated starting point for non-opioid drug leads, should also provide an opportunity for identifying novel molecular targets for future pain drugs. This review comprises several sections: the first focuses on Ziconotide as a therapeutic (including a historical retrospective and a clinical perspective); followed by sections on other promising Conus venom peptides that are either in clinical or pre-clinical development. We conclude with a discussion on why the outlook for discovery appears exceptionally promising. The combination of new technologies in diverse fields, including the development of novel high-content assays and revolutionary advancements in transcriptomics and proteomics, puts us at the cusp of providing a continuous pipeline of non-opioid drug innovations for pain. SIGNIFICANCE: The current opioid epidemic is the deadliest drug crisis in American history. Thus, this review on the discovery of non-opioid pain therapeutics and pathways from cone snail venoms is significant and timely.

AB - There have been numerous attempts to develop non-opioid drugs for severe pain, but the vast majority of these efforts have failed. A notable exception is Ziconotide (Prialt®), approved by the FDA in 2004. In this review, we summarize the present status of Ziconotide as a therapeutic drug and introduce a wider framework: the potential of venom peptides from cone snails as a resource providing a continuous pipeline for the discovery of non-opioid pain therapeutics. An auxiliary theme that we hope to develop is that these venoms, already a validated starting point for non-opioid drug leads, should also provide an opportunity for identifying novel molecular targets for future pain drugs. This review comprises several sections: the first focuses on Ziconotide as a therapeutic (including a historical retrospective and a clinical perspective); followed by sections on other promising Conus venom peptides that are either in clinical or pre-clinical development. We conclude with a discussion on why the outlook for discovery appears exceptionally promising. The combination of new technologies in diverse fields, including the development of novel high-content assays and revolutionary advancements in transcriptomics and proteomics, puts us at the cusp of providing a continuous pipeline of non-opioid drug innovations for pain. SIGNIFICANCE: The current opioid epidemic is the deadliest drug crisis in American history. Thus, this review on the discovery of non-opioid pain therapeutics and pathways from cone snail venoms is significant and timely.

U2 - 10.1016/j.jprot.2018.05.009

DO - 10.1016/j.jprot.2018.05.009

M3 - Journal article

C2 - 29777871

VL - 190

SP - 12

EP - 20

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -

ID: 232823266